Videos

Both patients and providers should recognize the benefits of early referrals to palliative care.

Ahmed Kotb, MD, vice president of US medical affairs, oncology, at AbbVie, discussed new findings from the REFINE trial and what they could mean for patients with myelofibrosis.

With several recent approvals, new CAR T therapies are having significant impacts in multiple myeloma treatment.

Ken Blount, PhD, chief scientific officer at Rebiotix, discusses the investigative treatment RBX2660 and its unique approach to treating Clostridioides difficile infection.

Ogi Kavazovic, co-founder and CEO of House Rx, discusses the company's technology platform and pharmacy service and how it can better enable community oncology pharmacy practices to offer medically integrated dispensing.

Tesh Khullar, co-founder and president of House Rx, discusses how social determinants of health can impact time to treatment initiation.

A panel of experts discuss allergic rhinitis and important counseling points and tactics. They review the current standard of care and identify specific treatment considerations for children, women, elderly, and others.

We're rowing in the same direction as pharmacists, so that what is of interest to a payer, PBMs and pharmacies, according to PQA.

We spoke with Kelly McAuliff, PharmD, BCOP, CSP, to learn about data being presented at the ASCO 2022 Annual Meeting.

Drs Haumschild, Howe, and Gilreath contribute their final perspectives for maximizing care management between providers and patients with myeloproliferative neoplasms.

Pharmacy specialists discuss quality initiatives in MPN management by sharing advice on assessing symptoms and patient adherence.

Just making sure that everybody has a seat at the table is the most important thing at PQA.

PQA wants to expand the types of services covered and report on the results of the current examples that are profiled in the SDOH guide.

The challenges in pharmacy are really a lack of standardization.

Pharmacists are ideally positioned to screen patients for estimation aids and then refer them to services.

Pharmacists are an important touch point for PQA, and they're starting small and thinking big.

Linaclotide (Linzess) is indicated in adults for treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.

PQA is also committed to national goals related to HIV and reducing HIV ending the epidemic.

PQA is focused on actually testing the feasibility and implementation of some of these measures as concepts.

Dong Xu, PhD, MS, curators' distinguished professor at the University of Missouri College of Engineering, discusses how the use of artificial intelligence may help develop new drug therapies targeting multiple disease states.

Karen Fancher, PharmD, BCOP, a member of the Patient Advisory Panel at the Hematology/Oncology Pharmacy Association (HOPA), explains how her experience as a patient with cancer and an oncology pharmacy specialist informs her work on HOPA’s Patient Advisory Panel.

Byron Yoshino, PharmD, CEO of Pharmacare Hawaii, discusses the future of the home infusion space within the United States in the coming years.

Sara Wettergreen, assistant professor in the department of Clinical Pharmacy, and Department of Family Medicine, at Skaggs School of Pharmacy and Pharmaceutical Sciences, on burnout and mental health concerns among pharmacy technicians

Without sufficient vitamin D exposure, bones can become thin, brittle, or misshapen; however, excessive amounts of vitamin D are toxic.

Dong Xu, PhD, MS, curators' distinguished professor at the University of Missouri College of Engineering, discusses how artificial intelligence is being used to develop new drug therapies for medical treatments targeting cancers and other diseases.

One example that has already been done in the past relates to understanding how to better measure insulin persistence.

Byron Yoshino, PharmD, CEO of Pharmacare Hawaii, discusses the rapidly growing home infusion space within Pharmacare Hawaii’s network of pharmacies.

Issues like medication access and transportation cost all impact a patient's ability to have access to medications and use them safely and effectively.

Murray Aitken, executive director of IQVIA Institute for Human Data Science, discusses whether patient out of pocket costs rose in 2021, and what the implications may be for the health care system and for patients in 2022.

It's really opening up the world for pharmacists to develop more meaningful measures and get at patient reported and clinical outcome measures.